Interleukin-1-beta (IL-1β)
TSD
Compared to placebo, no differences were observed in either treatment group for plasma IL-1β at the various assessed time points. TSD however increased levels of ex-vivo stimulated IL-1β release on day 4. These elevations were markedly attenuated compared to baseline (day -1) in the early start JNJ-54175446 (pre-TSD) treatment group A (JNJ-54175446 early start) and remained attenuated through to end of study day 10. Levels of ex-vivo stimulated IL-1β release in group B (JNJ-54175446 late start) were comparable on day 1 and day 4, but attenuated at day 10. A detailed description of the IL-1β and ex-vivo IL-1β stimulation results can be found in the supplemental material (supplemental Figs. 